Organization Profile

You just read:

Transition Therapeutics Announces Enrolment Completion of ELND005 Phase 2 Clinical Study in Agitation and Aggression in Patients with Alzheimer's Disease

News provided by

Transition Therapeutics Inc.

Mar 02, 2015, 06:02 ET